Benefits and harms of mammography screening.
Mammography screening for breast cancer is widely available in many countries. Initially praised as a universal achievement to improve women's health and to reduce the burden of breast cancer, the benefits and harms of mammography screening have been debated heatedly in the past years. This review discusses the benefits and harms of mammography screening in light of findings from randomized trials and from more recent observational studies performed in the era of modern diagnostics and treatment. The main benefit of mammography screening is reduction of breast-cancer related death. Relative reductions vary from about 15 to 25% in randomized trials to more recent estimates of 13 to 17% in meta-analyses of observational studies. Using UK population data of 2007, for 1,000 women invited to biennial mammography screening for 20 years from age 50, 2 to 3 women are prevented from dying of breast cancer. All-cause mortality is unchanged. Overdiagnosis of breast cancer is the main harm of mammography screening. Based on recent estimates from the United States, the relative amount of overdiagnosis (including ductal carcinoma in situ and invasive cancer) is 31%. This results in 15 women overdiagnosed for every 1,000 women invited to biennial mammography screening for 20 years from age 50. Women should be unpassionately informed about the benefits and harms of mammography screening using absolute effect sizes in a comprehensible fashion. In an era of limited health care resources, screening services need to be scrutinized and compared with each other with regard to effectiveness, cost-effectiveness and harms.
Institute of Health and Society, University of Oslo, N-0317, Oslo, Norway. magnus.loberg@medisin.uio.no.|Department of Transplantation Medicine, Oslo University Hospital, 0424, Oslo, Norway. magnus.loberg@medisin.uio.no.|Department of Epidemiology, Harvard School of Public Health, Boston, MA, 02115, USA. magnus.loberg@medisin.uio.no.
Magnus
M
Løberg
Department of Public Health, Aarhus University, 8000, Aarhus C, Denmark. mette.lise.lousdal@publ.au.dk.
Mette Lise
ML
Lousdal
Institute of Health and Society, University of Oslo, N-0317, Oslo, Norway. micahel.bretthauer@medisin.uio.no.|Department of Transplantation Medicine, Oslo University Hospital, 0424, Oslo, Norway. micahel.bretthauer@medisin.uio.no.|Department of Epidemiology, Harvard School of Public Health, Boston, MA, 02115, USA. micahel.bretthauer@medisin.uio.no.|Department of Medicine, Sorlandet Hospital, 4604, Kristiansand, Norway. micahel.bretthauer@medisin.uio.no.
Michael
M
Bretthauer
Institute of Health and Society, University of Oslo, N-0317, Oslo, Norway. mkalager@hsph.harvard.edu.|Department of Epidemiology, Harvard School of Public Health, Boston, MA, 02115, USA. mkalager@hsph.harvard.edu.|Telemark Hospital, 3710, Skien, Norway. mkalager@hsph.harvard.edu.
Mette
M
Kalager
D001943:Breast Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000401:mortality; D055088:Early Detection of Cancer / Q000009:adverse effects / Q000379:methods; D005260:Female; D006801:Humans; D008327:Mammography / Q000009:adverse effects / Q000379:methods; D008403:Mass Screening; D009026:Mortality; D012680:Sensitivity and Specificity